CY1124994T1 - Ενωσεις-αναστολεις της βτκ - Google Patents

Ενωσεις-αναστολεις της βτκ

Info

Publication number
CY1124994T1
CY1124994T1 CY20221100128T CY221100128T CY1124994T1 CY 1124994 T1 CY1124994 T1 CY 1124994T1 CY 20221100128 T CY20221100128 T CY 20221100128T CY 221100128 T CY221100128 T CY 221100128T CY 1124994 T1 CY1124994 T1 CY 1124994T1
Authority
CY
Cyprus
Prior art keywords
btk
inhibiting compounds
compounds
salts
compositions
Prior art date
Application number
CY20221100128T
Other languages
English (en)
Inventor
Kenneth James Henry, Jr.
Albert Khilevich
Steven Lee Kuklish
Katherine Marie PARTRIDGE
Steven James Quimby
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1124994T1 publication Critical patent/CY1124994T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η εφεύρεση παρέχει ενώσεις οι οποίες είναι Αναστολείς της ΒΤΚ, φαρμακευτικά αποδεκτά άλατα, φαρμακευτικές συνθέσεις αυτών, και μεθόδους χρήσης αυτών των ενώσεων, αλάτων, ή συνθέσεων για την αγωγή αυτοάνοσων νόσων όπως της Ρευματοειδούς Αρθρίτιδας.
CY20221100128T 2017-11-06 2022-02-15 Ενωσεις-αναστολεις της βτκ CY1124994T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762581967P 2017-11-06 2017-11-06
PCT/US2018/058104 WO2019089512A1 (en) 2017-11-06 2018-10-30 Btk inhibitor compounds

Publications (1)

Publication Number Publication Date
CY1124994T1 true CY1124994T1 (el) 2023-01-05

Family

ID=64277913

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100128T CY1124994T1 (el) 2017-11-06 2022-02-15 Ενωσεις-αναστολεις της βτκ

Country Status (34)

Country Link
US (1) US11542249B2 (el)
EP (1) EP3707133B1 (el)
JP (1) JP6920553B2 (el)
KR (1) KR102410202B1 (el)
CN (1) CN111278818B (el)
AR (1) AR113796A1 (el)
AU (1) AU2018360478B2 (el)
BR (1) BR112020006749A2 (el)
CA (1) CA3080123C (el)
CL (1) CL2020001089A1 (el)
CR (1) CR20200183A (el)
CY (1) CY1124994T1 (el)
DK (1) DK3707133T3 (el)
DO (1) DOP2020000103A (el)
EA (1) EA039398B1 (el)
EC (1) ECSP20024395A (el)
ES (1) ES2904843T3 (el)
HR (1) HRP20220178T1 (el)
HU (1) HUE057987T2 (el)
IL (1) IL273778B (el)
JO (1) JOP20200104A1 (el)
LT (1) LT3707133T (el)
MA (1) MA50561B1 (el)
MD (1) MD3707133T2 (el)
MX (1) MX2020004435A (el)
PE (1) PE20201168A1 (el)
PL (1) PL3707133T3 (el)
PT (1) PT3707133T (el)
RS (1) RS62805B1 (el)
SG (1) SG11202003178PA (el)
SI (1) SI3707133T1 (el)
TW (1) TWI694995B (el)
UA (1) UA126079C2 (el)
WO (1) WO2019089512A1 (el)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3972603B1 (en) * 2019-05-23 2024-09-04 Novartis AG Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2444144T3 (es) * 2007-10-23 2014-02-24 F. Hoffmann-La Roche Ag Nuevos inhibidores de quinasa
CN103038233B (zh) * 2010-05-07 2017-06-20 吉利德康涅狄格有限公司 吡啶酮和氮杂吡啶酮化合物及使用方法
AR082590A1 (es) * 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
DK2718270T3 (da) 2011-06-10 2022-08-01 Merck Patent Gmbh Sammensætninger og fremgangsmåder til fremstillingen af pyrimidin- og pyridinforbindelser med btk-hæmmende aktivitet
WO2014093230A2 (en) * 2012-12-10 2014-06-19 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
GB2516303A (en) * 2013-07-18 2015-01-21 Redx Pharma Ltd Compounds
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
US10526309B2 (en) * 2015-10-02 2020-01-07 The University Of North Carolina At Chapel Hill Pan-TAM inhibitors and Mer/Axl dual inhibitors

Also Published As

Publication number Publication date
ECSP20024395A (es) 2020-06-30
AU2018360478B2 (en) 2020-09-17
EA202090843A1 (ru) 2020-07-24
JP6920553B2 (ja) 2021-08-18
US11542249B2 (en) 2023-01-03
CA3080123C (en) 2021-11-09
IL273778B (en) 2022-06-01
MA50561A (fr) 2020-09-16
MD3707133T2 (ro) 2022-07-31
EA039398B1 (ru) 2022-01-24
SG11202003178PA (en) 2020-05-28
KR20200060480A (ko) 2020-05-29
US20200290997A1 (en) 2020-09-17
DK3707133T3 (da) 2022-01-03
HRP20220178T1 (hr) 2022-04-29
TW201930293A (zh) 2019-08-01
CN111278818B (zh) 2023-03-28
CL2020001089A1 (es) 2020-10-23
AU2018360478A1 (en) 2020-04-23
BR112020006749A2 (pt) 2020-10-06
JOP20200104A1 (ar) 2022-10-30
EP3707133A1 (en) 2020-09-16
CA3080123A1 (en) 2019-05-09
DOP2020000103A (es) 2020-09-15
ES2904843T3 (es) 2022-04-06
WO2019089512A1 (en) 2019-05-09
MA50561B1 (fr) 2022-03-31
HUE057987T2 (hu) 2022-06-28
KR102410202B1 (ko) 2022-06-22
TWI694995B (zh) 2020-06-01
EP3707133B1 (en) 2021-12-15
MX2020004435A (es) 2020-08-06
JP2021501749A (ja) 2021-01-21
AR113796A1 (es) 2020-06-10
PE20201168A1 (es) 2020-10-28
CR20200183A (es) 2020-05-30
IL273778A (en) 2020-05-31
LT3707133T (lt) 2022-01-25
CN111278818A (zh) 2020-06-12
PL3707133T3 (pl) 2022-04-04
RS62805B1 (sr) 2022-02-28
UA126079C2 (uk) 2022-08-10
SI3707133T1 (sl) 2022-02-28
PT3707133T (pt) 2022-01-27
NZ764452A (en) 2023-09-29

Similar Documents

Publication Publication Date Title
CY1121195T1 (el) Παραγωγα τετραϋδροναφθαλενιου που αναστελλουνπρωτεϊνη mcl-1
CY1122279T1 (el) Ενωσεις ναφθυριδινης αναστολεις κινασης jak
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1124959T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
CY1121433T1 (el) Παραγωγα δικυκλικων ετεροκυκλυλιων ως αναστολεις irak4
CY1124918T1 (el) Ρυθμιστες ccr2
EA201890325A1 (ru) Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний
CY1123475T1 (el) Αναστολεις της ειδικης για λυσινη απομεθυλασης-1
CY1123451T1 (el) Αγωνιστες τριαζολης του υποδοχεα αρj
CY1125205T1 (el) Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων
CY1119678T1 (el) Πυριμιδινονες ως αναστολεις τελεστη χια
CY1120935T1 (el) Νεες συνθεσεις, χρησεις και μεθοδοι για την παρασκευη αυτων
CY1124749T1 (el) Παραγωγα διπυραζολιου χρησιμα για την θεραπεια αυτοανοσων νοσηματων
CY1121746T1 (el) Αναστολεις mgat2 τετραζολονο-υποκατεστημενης διυδροπυριδινονης
CY1121550T1 (el) Ενωσεις πυριδινης πλαδιενολιδης και μεθοδοι χρησης
CY1125047T1 (el) Διεργασιες για την παρασκευη ενωσεων τυπου οξαθειαζινης
CY1122613T1 (el) Παραγωγα 4-οξο-3,4-διυδρο-1,2,3-βενζοτριαζινης ως ρυθμιστες toy gpr139
CL2019002240A1 (es) Dendrímeros terapéuticos.
CY1125169T1 (el) ΕΝΩΣΕΙΣ ΑΜΙΝΟΠΥΡΑΖΙΝΟ ΔΙΟΛΗΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΡΙ3Κ-γ
CY1123592T1 (el) Αναστολεας κινασης aurora a
CY1126031T1 (el) Συνθεσεις για καθαρισμο του παχεος εντερου και την αντιμετωπιση γαστρεντερικων διαταραχων
CY1122287T1 (el) Ενωσεις χρησιμες για την αναστολη toy ror-γαμμα-τ
CY1123576T1 (el) Συμπυκνωμενα παραγωγα θειοφαινιου χρησιμα ως αναστολεις του napi-iib
CY1121345T1 (el) Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
CY1125297T1 (el) Αναστολεις της il-8 για χρηση στην αγωγη της περιφερικης νευροπαθειας που επαγεται απο χημειοθεραπεια